Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Grok AI Faces Global Scrutiny Over Safeguard Failures and Illegal Content on X 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Trump Blocks HieFo’s Emcore Chip Assets Deal Over National Security Concerns 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
NEW YORK, March 13, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers ReWalk Robotics Ltd. securities (NASDAQ:RWLK) pursuant and/or traceable to ReWalk’s initial public offering on or about September 12, 2014 of the important March 27, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for ReWalk investors under the federal securities laws.
To join the ReWalk class action, go to http://rosenlegal.com/cases-1050.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, the Registration Statement and Prospectus issued in connection with ReWalk’s initial public offering contained materially misleading statements and/or failed to disclose that ReWalk was unprepared and/or unable to comply with applicable “special controls” requirements or to provide the FDA with a postmarket surveillance study as required by the FDA for ReWalk to maintain ongoing sales of its products. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 27, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1050.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
